The token is for just one goal! The help patients with mental disorders or serious psychiatric issues.
Since the start of the COVID pandemic, the number of people with anxiety and depression increse 25% - OMS Numbers - and with our product produced with substances found mainly in mushrooms, we hope to soften these symptoms in the patients
And our products can only be purchased using BIOTRIP tokens.
The BIOTRIP Token is used for purchases of the BIOCASE products and every commercial sales will be crypto anchored only.
Drug Discovery and Development
- R & D
- DNA Arrays
- Proof of Concept
- Metabolism Studies
- Full cGMP
- Release Tests
Open Token to Public
Token with limited distribution. And to use only for BIOCASE products purchases.
The amount raised will be destined for new clinical trials involving the psychoactive substances present in mushrooms, Psilocybin and Psilocin, in addition to the production of new products.
Network used to exchange tokens will be SOLANA. The fee`s are lower and it is faster and safer than other in the marketplace.
First, in Brazil, we`ll be using GROOTBIT as our initial exchange, but we tend to expand for others exchange in the world
The products to be sold with the token, are mainly produts with substances found in mushrooms, Psilocybin and Psilocin.
We are using, smart contracts and the SOLANA Network, for a better transaction security.
BIOTRIP will be released on the basis of SOLANA platform; Solana’s network allows for a theoretical throughput of 65,000 transactions per second, a significant jump from Bitcoin’s seven transactions per second and Ethereum’s 15 transactions per second. (TPS). Combined with high gas fees on ETH’s blockchain, Solana offers a much lower barrier to entry, helping to increase its user base rapidly.
Transactions on Solana cost a fraction of the price of other blockchains, averaging at $0.00025. Solana attracts users worldwide due to its low costs and increased throughput capability.
Support of this standard guarantees the compatibility of the token with third-party services (wallets, exchanges, listings, etc.), and provides easy integration.
Total token supply - 30,000,000
The project took form from the concomitant from BIOCASE Brazil on use of psychedelic substances, like psilocibina and psilocina, to treat mental illness and/or serious psychiatric issues.
According to the company's business plan, the entire commercial process related to the commercial product resulting from research with Psilocybe mushrooms will be anchored in the cryptocurrency. To acquire the product or the technology licensing in Brazil or in other parts of the world, the interested party must purchase through the company's cryptocurrency.
In Brazil, the product will probably only be available for hospitals, clinics and research centers, with sales online or not, but always wholesale and always by Legal Entities. The purchase of Crypto by Individuals will also be possible, but this type of buyer/investor will not be able to receive the final products, remaining only in possession of their cryptocurrencies.
The group is launching the BCASE token with the aim of carrying out transactions for the digital environment – more secure, advantageous and decentralized. The token will be used to purchase Biocase Brasil's psychedelic substance products
The intent to launch the BCASE Token on Solana Network, for a faster and cheaper experience.
Our first study, now in 2nd Phase of clinical evaluation, encompasses the end of life that brings a very great psychological and social burden to the patient, and also to the people close to him. In addition to the pain and physical limitation resulting from the progression of diseases, the psychological suffering due to the pain itself, the fear of death, dependence and feelings of attachment and abandonment, has a great harmful impact on the quality of life of this patient. In this first study, we are addressing the therapeutic effects of Psilocybin in the treatment of Fear of Death, in addition to the evaluation of secondary endpoints such as depression and sleep quality. The study carried out by Dr. Cesar Camara, CEO of Biocase Brasil, includes cancer patients at risk of death, with low life expectancy and with anxiety disorders, according to clinical diagnosis (CID) and anxiety score through HADS and GAD-7.
One of the goals of cancer treatment is to promote the relief of physical and psychological symptoms of patients, especially when there is little possibility of cure, resulting in a better quality of life. The prevalence of anxiety and depression in these patients may vary according to the type of cancer, time of diagnosis, treatment site and life expectancy.
In a study carried out in 2019, the World Health Organization (WHO) pointed out that Brazil has, compared to all other countries in the world, the largest number of anxious people. There are 18.6 million Brazilians who suffer from some type of anxiety disorder. According to the epidemiological study, the lifetime prevalence of depression in Brazil is around 15.5%.
Moreover, Brazil has a legal structure that permits faster clinical trial development involving natural psychedelic presents in mushrooms and vegetables forbidden in other countries
The scientific journals "The New England Journal of Medicine" and "Nature" recently published consistent results of research on the use of psychedelics in the treatment of depression and post-traumatic stress.
The number of high reputable studies publisher grew 300% over the last 10 years.
Psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine) is an indole alkaloid compound derived from tryptophan, an agonist of serotonergic receptors and has an affinity for 5HT2A receptors. The substance is found in fungi, mainly in mushrooms of the Psilocybe cubensis family. The psychoactive substance present in mushrooms induces changes in sensory, behavioral, emotional and common sense perception about oneself, including reductions in depressive and anxiety symptoms. And these profoundly occurring changes are characteristic of an altered state of consciousness and may involve mystical-type experiences.
With the studies carried out, Biocase has a structure with the basic licenses for the production of the drug in partnership with the national laboratory CERTBIO – (Laboratory for the Evaluation and Development of Biomaterials of the Northeast) University of Paraíba, which will boost research, extraction and production substances for the purpose of treating patients in clinical conditions. Second step: Authorization for testing on animals and then on humans. Biocase has a Study and Research Center (CEP) in São Paulo suitable for carrying out Clinical Studies in Humans called Instituto Alma Viva;
The resurgence of research into psychedelics has continued to thrive over the past year. Dozens of trials and hundreds of studies have been published in 2021, expanding the depth and scope of scientific inquiry in this flourishing space.
Scientists treating depression and a range of other mental illnesses have been running controlled trials using MDMA and psychedelic drugs
Medical treatments using psychedelic drugs such as psilocybin – derived from certain mushrooms
The Johns Hopkins Center for Psychedelic and Consciousness Research is leading the way in exploring innovative treatments using psilocybin